Skip to main content

Advertisement

SpringerLink
Log in

Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects

  • Published:
Journal of Neurology Aims and scope Submit manuscript

An Erratum to this article was published on 01 February 2008

Abstract

Introduction

Although IVIg is highly effective in several autoimmune neuromuscular disorders (neuropathies, myopathies and neuromuscular junction disorders), its effectiveness in autoimmune or neuroinflammatory CNS diseases, with the exception of multiple sclerosis, has not been explored. Emerging data suggest that IVIg may have a role not only in certain antibody-mediated CNS diseases but also in some neurodegenerative disorders associated with “neuroinflammation” mediated by proinflammatory cytokines.

Methods

Data from a previously reported controlled study conducted in patients with stiff person syndrome (SPS) are presented as a paradigm of a CNS disorder associated with specific autoantibodies responding to IVIg. Emerging data using IVIg in various neuroinflammatory and neurodegenerative conditions such as Alzheimers disease, postpolio syndrome (PPS), fibrotic disorders, chronic painful conditions and narcoplepsy are summarized.

Results

On the basis of a double-blind placebo-controlled trial conducted in SPS patients with high anti-GAD antibodies, IVIg was shown to be effective resulting in improvement of stiffness and heightened sensitivity scores and increasing the patients’ ability to carry out daily activities. In SPS, IVIg also suppressed the anti-GAD antibodies titers probably via an anti-idiotypic effect. A controlled study in patients with PPS, showed reduction in cytokines in serum and CSF with concomitant improvement in the patients’ strength and ability to carry out their daily activities. The effect of IVIg in a small number of patients with Alzheimer’s disease was promising by reducing the ADAS-cog scores, suggesting a reversal of disease progression. IVIg has been shown to have an effect on tissue fibrosis and in certain subacute painful conditions by suppressing cytokines that mediate fibrosis or pain. In another uncontrolled study, IVIg reduced the number of cataplectic attacks in narcolepsy patients.

Conclusions

IVIg is effective in anti-GAD-positive patients with SPS. Whether it is also effective in other GAD-positive CNS disorders such as epilepsies, cerebellar degenerations or Batten’s disease need to be studied in control trials. Emerging data suggest that IVIg, by suppressing proinflammatory cytokines, may exert a beneficial effect in patients with Alzheimer’s disease, postpolio syndrome, chronic pain syndromes, fibrotic disorders and narcolepsy. Controlled studies are being planned or conducted to substantiate the benefit of IVIg in neurodegenerative disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Akiyama H, Barger S, Barnum S et al. (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421

    Article  PubMed  CAS  Google Scholar 

  2. Amato AA, Cornman EW, Kissel JT (1994) Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 44:1652–1654

    PubMed  CAS  Google Scholar 

  3. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99–104

    Article  PubMed  CAS  Google Scholar 

  4. Askanas V, Dalakas MC, Engel WK (2006) Inclusion-body myositis: clinical and pathologic aspects, and basic research potentially relevant to treatment. Neurology 24(Suppl 1):66

    Google Scholar 

  5. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689–1690

    Article  PubMed  CAS  Google Scholar 

  6. Barker RAMC (1997) Successful treatment of stiff-man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 62:426

    Article  PubMed  CAS  Google Scholar 

  7. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000

    Article  PubMed  CAS  Google Scholar 

  8. Dalakas MC (1995) Pathogenetic mechanisms of postpolio syndrome: Morphological, electrophysiological, virological and immunopathological correlations. Ann NY Acad Sci 753:167–185

    PubMed  CAS  Google Scholar 

  9. Dalakas MC (1998) Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 55:1509–1512

    Article  PubMed  CAS  Google Scholar 

  10. Dalakas MC (1999) Autoantibodies and immunopathogenesis of the stiff-person syndrome. In: Levy LM (moderator) The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 131:522–530

    PubMed  Google Scholar 

  11. Dalakas MC (1999) Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opinion in Neurology 12:403–409

    Article  CAS  Google Scholar 

  12. Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531–1535

    PubMed  CAS  Google Scholar 

  13. Dalakas MC, Li M, Fujii M, Jacobowitz DM (2001) Stiff-person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 57:780–785

    PubMed  CAS  Google Scholar 

  14. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immunoglobulin for stiffperson syndrome. N Engl J of Med 345:1870–1876

    Article  CAS  Google Scholar 

  15. Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327

    PubMed  CAS  Google Scholar 

  16. Dalakas MC (2002) Proinflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome? J Neurol Sci 205:5–8

    Article  PubMed  Google Scholar 

  17. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982

    Article  PubMed  CAS  Google Scholar 

  18. Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neurological disorders: evidence-based indications and safety profile. Pharmacol Therapeutics 102:177–193

    Article  CAS  Google Scholar 

  19. Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375

    Article  PubMed  CAS  Google Scholar 

  20. Dalakas MC (2004) Inhibiting leucocyte recruitment to the brain by IVIg. Is it relevant to the treatment of demyelinating CNS disorders? (Editorial) Brain 127:2569–2571

    Article  PubMed  Google Scholar 

  21. Dalakas MC (2005) The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 252(S):19–25

    Article  CAS  Google Scholar 

  22. Dalakas MC (2006) Inflammatory, immune and viral aspects of inclusion body myositis. Neurology 66(Suppl):533–538

    Google Scholar 

  23. Dalakas MC (2006) Signaling pathways and immunobiology of inflammatory myopathies. Nature Clinic Practice 2:219–227

    Article  CAS  Google Scholar 

  24. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905–908

    Article  PubMed  CAS  Google Scholar 

  25. Daw K, Ujihara N, Atkinson M, Powers AC (1996) Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156:818–825

    PubMed  CAS  Google Scholar 

  26. Dinkel K MH, Jury KM et al. (1998) Inhibition of gama-aminoutric acid synthesis by glutamic acid decarboxylase autoantibodies in Stiff-Man syndrome. Ann Neurol 44:194–201

    Article  PubMed  CAS  Google Scholar 

  27. Dodel R, Hampel H, Depboylu C et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol 52:253–256

    Article  PubMed  CAS  Google Scholar 

  28. Dodel RC, Du Y, Depboylu C et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:1472–1474

    Article  PubMed  CAS  Google Scholar 

  29. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M (2003) Human anti-beta-amyloid antibodies block betaamyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126:1935–1939

    Article  PubMed  Google Scholar 

  30. Ellis MT, Atkinson AM (1996) The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nature Medicine 2:148–153

    Article  PubMed  CAS  Google Scholar 

  31. Goebel A, Netal S, Schedel R, Sprotte G (2002) Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 3:119–127

    Article  PubMed  Google Scholar 

  32. Goebel A Goebel A, Vogel H et al. (2005) Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol 162:184–189

    Article  PubMed  CAS  Google Scholar 

  33. Goebel A, Stock M, Deacon R, Sprotte G,Vincent A (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463–464

    Article  PubMed  Google Scholar 

  34. Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T (2002) Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 5:9–13

    Article  Google Scholar 

  35. Gonzalez H, Khademi M, Andersson M et al. (2004) Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150:139–144

    Article  PubMed  CAS  Google Scholar 

  36. Gonzales H et al. (2006) Intravenous immunoglobulin for the post-polio syndrome; a randomized controlled trial. Lancet Neurology 5:493–500

    Article  CAS  Google Scholar 

  37. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C et al. (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58:225–230

    Article  PubMed  CAS  Google Scholar 

  38. Huizing M, Rakocevic G, Sparks SE, Mamali I, Goldfarb L, Krasnewich D, Gahl WA, Dalakas MC (2004) Hypoglycosylation of a-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metabolism 81:196–202

    Article  CAS  Google Scholar 

  39. Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P (2004) IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127:2649–2656

    Article  PubMed  Google Scholar 

  40. Levy LM, Levy-Reis I, Fujii M, Dalakas MC (2005) Brain g-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62:970–974

    Article  PubMed  Google Scholar 

  41. Meinck HM, Ricker K, Hulser PJ, Solimena M (1995) Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 242:134–142

    Article  PubMed  CAS  Google Scholar 

  42. Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P et al. (2004) Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 63:2146–2148

    PubMed  CAS  Google Scholar 

  43. Pearce DA, Atkinson M, Tagle DA (2004) Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 63:2001–2005

    PubMed  CAS  Google Scholar 

  44. Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K et al. (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55:46–50

    PubMed  CAS  Google Scholar 

  45. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC, Ortqvist E, Hampe CS (2005) Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 75:7755–7762

    Google Scholar 

  46. Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes. Brain 128:1887–1896

    Article  PubMed  Google Scholar 

  47. Rakocevic G, Raju R, Semino-Mora, Dalakas MC (2006) Stiff Person Syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (In press)

  48. Schmidt J, Voss JG, Raju R, Dalakas MC (2004) Effect of immunotherapy on expression of cytokines and chemokines in relation to beta-amyloid and ubiquitin in the muscle of patients with sporadic inclusion body myositis. Ann Neurol 56:63

    Google Scholar 

  49. Schmidt J et al. (2005) Distinct interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Neurology 64(Suppl 1):A331–A332

    Google Scholar 

  50. Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Int Med 121:259–262

    PubMed  CAS  Google Scholar 

  51. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555–1560

    Article  PubMed  CAS  Google Scholar 

  52. Vasconcelos OM, Raju R, Dalakas MC (2002) GNE mutations in an American family with quadriceps-sparing IBM. Neurology 59:1776–1780

    PubMed  CAS  Google Scholar 

  53. Vasconcelos OM, Dalakas MC (2003) Therapies for stiff person syndrome. Current Treatment Options in Neurology 5:79–90

    PubMed  Google Scholar 

  54. Vernino S, Lennon VA (2004) Autoantibody profiles and neurological correlations of Thymoma. Clin Cancer Res 10:7270–7275

    Article  PubMed  CAS  Google Scholar 

  55. Weinberger DR (2001) Anxiety at the frontier of molecular medicine. N Engl J Med 344:1247–1249

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuromuscular Diseases Section, NINDS National Institutes of Health, Building 10, Room 4N248, 10 Center Drive MSC, Bethesda, MD 20892-1382, USA

    Marinos C. Dalakas M.D.

Authors
  1. Marinos C. Dalakas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marinos C. Dalakas M.D..

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00415-008-0881-z.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalakas, M.C. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. J Neurol 253 (Suppl 5), v25–v32 (2006). https://doi.org/10.1007/s00415-006-5004-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-5004-0

Key words

Search

Navigation